Treatment Satisfaction of Using OmniPod System Compared With Conventional Insulin Pump in Adults With Type 1 Diabetes

Rabin Medical Center30 enrolled

Overview

Randomized, two arms, open study in order to evaluate treatment satisfaction of using OmniPod system compared with conventional insulin pump in adults with type 1 diabetes. The study will include two consecutive 12 weeks treatment periods. According to randomization, each patient will be treated consecutively with both treatment arms: 12 weeks with OmniPod system and than 12 weeks with patient's previous insulin pump or vice versa.

A Randomized, two arms, open, crossover study in order to evaluate treatment satisfaction of using OmniPod system compared with conventional insulin pump in adults with type 1 diabetes. The study will include two consecutive 12 weeks treatment periods. According to randomization, each patient will be treated consecutively with both treatment arms: 12 weeks with OmniPod system and than 12 weeks with patient's previous insulin pump or vice versa. Study will consist of 4 clinic visits taking place at -2,0,12 and 24 weeks and additional 4 telephone visits taking place at 4,8,16 and 20 weeks. In addition, patients will be invited one week prior to visit 5 and visit 8 in order to insert a continuous glucose sensor. Patients will complete DTSQ and Comfort \& Function questionnaires at weeks 0, 12 and 24, before and at the end of each study arm. On each clinical visits the following parameters will be evaluated: vital signs, HbA1c, 4 and 7 points glucose profile, hypoglycemia events, hyperglycemia events and pump related technical problems. The telephone visits will include pump related technical problems solving and AE/SAE reporting.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Type 1 Diabetes

Interventions

OmniPod systemDEVICE

Patients will be treated with the OmniPod system for 12 weeks

Patient's conventional pumpDEVICE

patients will be treated with their conventional pump for 12 weeks

Eligibility

Sex: ALLMin age: 18 YearsMax age: 35 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Type 1 diabetes diagnosed at least 1 year prior to study entry 2. Use of continuous subcutaneous insulin infusion therapy for at least one year 3. Age: 18-35 years old 4. HbA1c \>8.0 5. At least 4 self blood glucose measurements per day 6. No more than one severe hypoglycaemic or ketoacidosis episode within the past year and none within the past month 7. Capable of reading pump screen in English 8. Able to understand and sign subject informed consent forms Exclusion Criteria: 1. Any significant disease or conditions, including psychiatric disorders that in the opinion of the principal investigator are likely to effect subject compliance or the subjects ability to complete the study. 2. Patients participating in other device or drug studies 3. Clinical diagnosis of hypoglycaemic unawareness 4. Known dermal hypersensitivity to products that contain medical adhesive 5. Taking prescription medications that could complicate the management of glycemic control. 6. Inability to understand/complete the Treatment satisfaction questionnaire

Locations (1)

Schnider children's medical center

Petah Tikva, Israel

Outcomes

Primary Outcomes

Treatment satisfaction

Time frame: Diabetes Treatment Satisfaction Questionnare (DTSQ) will be completed at baseline, 12 and 24 weeks

Secondary Outcomes

Comfort and function

Time frame: Comfort and function questionnaires will be completed at weeks 0,12 and 24.

HbA1C

Time frame: HbA1C will be measured at screening, baseline, 12 weeks and 24 weeks

Fructosamine

Time frame: Fructosamine will be measured at baseline,12 and 24 weeks

7 points glucose profile

Time frame: diary will be completed before every clinical visit

Pump related technical difficulties

Time frame: pump related technical difficulties will be analyzed every telephone visit

continuous glucose measurements

Time frame: continuous glucose sensor will be inserted one week before visits 5 and 8

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.